Other ESR1 alterations found in endocrine therapy resistant breast tumors include point mutations in the ligand-binding domain (LBD)[23] [Figure 1C] that confer constitutive hormone-independent activation of ER and are now a well-described mutational mechanism identified in up to 40% of metastatic breast cancer cases[24]. Here, ESR1 is linked to breast carcinoma.